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From patent to patient: analysing
access to innovative cancer drugs
Eva Sharpe, Richard Hoey, Christina Yap and Paul Workman, Paul.Workman@icr.ac.uk
Analysis of cancer drugs licensed through the European Medicines Agency (EMA) in 2000–2016 shows
that the number of authorisations increased over that timeframe. The median number of licensed drugs
each year rose from six for 2000–2008 to 13.5 for 2009–2016. Over 2000–2016, there were 64 drug
authorisations for haematological, 15 for breast, and 12 for skin cancer, but none for oesophageal, brain,
bladder, or uterine cancer. Only 6% of authorisations included a paediatric indication. The average time
for a drug to progress from patent priority date to availability on the National Health Service (NHS)
increased from 12.8 years for drugs licensed in 2000–2008 to 14.0 years for those approved in 2009–2016.
There was evidence that the most innovative drugs were not being prioritised for EMA licensing and
NICE approval.
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Over the past two decades, we have seen a
range of new targeted drugs and immu-
notherapies developed for cancer, enabled by
our greatly enhanced understanding of the
genomics and biology of human malignancies
[1,2]. However, although there have been dra-
matic improvements in survival for some cancer
types, progress against others has been much
more modest. Many new targeted cancer
treatments are initially highly effective, only for
cancers to adapt, evolve, and become resistant
[3,4]. Thus, there is an urgent need for innovative
new treatments with novel mechanisms of ac-
tion, so that we can treat cancers in new ways,
often involving the use of rationally selected
novel drug combinations, to avoid or overcome
drug resistance [3,5].
There is now growing scrutiny of the whole
ecosystem for cancer therapeutics, and whetherPlease cite this article in press as: Sharpe, E. et al. From
drudis.2020.01.004
1359-6446/ã 2020 The Authors. Published by Elsevier Ltd. This is an o
https://doi.org/10.1016/j.drudis.2020.01.004 it is sufficiently supporting the discovery and
development of innovative new treatments,
especially for those cancers of highest unmet
need for which outcomes remain poor [6].
Cancer specialists and patients in many coun-
tries are concerned about how to ensure that
healthcare systems can deliver rapid access to
the latest effective treatments, especially given
the high prices of many new drugs [7]. In Eng-
land and Wales, new drugs must not only pass
through clinical trials and authorisation, but also
be judged by the UK National Institute for Health
and Care Excellence (NICE) as cost-effective for
use on the NHS [8]. This has sometimes been
perceived as an additional barrier for patients in
accessing the most innovative treatments.
The Institute of Cancer Research, London, is a
global leader in academic cancer drug discovery,
development, and commercialisation, and colla-
borates extensively with industry. We have a keen patent to patient: analysing access to innovative cancer dru
pen access article under the CC BY license (http://creativecommons.orginterest in understanding the extent to which
current policy, regulation, and economic frame-
works are supporting and rewarding the rapid
development of innovative cancer drugs. In this
report, we retrospectively analyse all cancer drugs
newly licensed by the European Medicines
Agency (EMA) between 2000 and 2016, with the
aim of exploring the following questions: (i) what
drugs have come through the pipeline and for
which types of cancer?; (ii) how long did it take
these to reach patients on the NHS? And (iii) is the
system encouraging radical innovation?
Methodology
For consistency, we used the following terms
throughout this report: (i) licensing: the evaluation
undertaken by the EMA leading to a drug receiving
an authorisation; (ii) authorisation: a licence from
the EMA for use of a drug for a specific cancer
indication; (iii) indication:a specific licensed use ofags, Drug Discov Today (2020), https://doi.org/10.1016/j.
/licenses/by/4.0/).
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isations for different indications, such as for dif-
ferent cancers; (iv) appraisal: the evaluation process
undertaken by NICE to decide whether a drug
should be made available on the NHS; and (v)
approval: indicates when a drug has received a
positive appraisal from NICE. This term can also be
used to mean drug authorisation but, to avoid
confusion, we have avoided doing so in this report.
We identified all cancer drugs first authorised
by the EMA and listed on its database after 1
January 2000 and before 31 December 2016. We
also recorded the total number of authorised
cancer indications for each drug. We defined
cancer drugs as those belonging to code L,
which covers antineoplastic and immunomo-
dulating agents within the WHO Anatomical
Therapeutic Chemical Classification System. We
looked at the number of EMA authorisations
each year and also split the data into two time
periods, from 2000 to 2008, and from 2009 to
2016, and carried out comparative analyses.
We examined how quickly drugs moved along
the development pipeline from the patent pri-
ority date, through to the registration of the
initial Phase I clinical trial, the award of the EMA
authorisation licence, and, where applicable, the
publication by NICE of its final appraisal deter-
mination evaluating the drug for use on the
NHS. We chose these milestones because it was
possible to collect data on them in a consistent,
standardised manner, which was not always
feasible for other events, such as the initial
publication describing a drug or the reporting of
data from the registration trial.
We also adapted published methodology [9]
to assign a level of innovation to each drug, and
to explore what implications this had for de-
velopment and approval. We considered a drug
highly innovative if it acted against a new mo-
lecular target or via a novel mechanism, repre-
sented a novel class of compound in an area of
high unmet need, was novel in its application, or
offered improved targeting through use of a
biomarker. Within this category, we identified a
subgroup we classed as representing the very
highest level of innovation: drugs acting against
novel targets or with a new mechanism of
action. Moderately innovative drugs were those
representing a novel class of compounds out-
side areas of high unmet need, or with reduced
adverse effects or interactions, or having im-
proved delivery or pharmacokinetics. Low in-
novation drugs were those with novel structures
but within an existing class of compounds, or
with improved production.
We aimed to assess how effectively the cancer
therapeutics ecosystem is delivering drugs forPlease cite this article in press as: Sharpe, E. et al. From
drudis.2020.01.004
2 www.drugdiscoverytoday.compatients, especially agents with high innovation;
how long it is taking; and what improvements
could be made. Our study focuses on drugs that
had received regulatory authorisation from the
EMA. It does not investigate the cancer drug
ecosystem more widely, for example by looking
at drugs that progressed through trials but were
never licensed by the EMA, or that were still
passing through clinical trials at the point of
analysis. Detailed data are provided in the
Supplemental information online.
Our statistical analysis is primarily descriptive.
To assess the trend for EMA drug authorisations
from 2000 to 2016, we display scatter plots both
for the overall number and by innovation cat-
egory. Smooth trends with 95% confidence
intervals (CI) were fitted by means of generalised
additive models (GAM) with thin plate regres-
sion splines, via automatic smoothness estima-
tion [10]. Violin plots with embedded boxplots
are used to visualise the underlying data dis-
tribution of continuous measures. For continu-
ous variables, summary statistics of mean
(standard deviation) and median (lower and
upper quartiles) are displayed for normal data
and skewed data, respectively. To assess differ-
ences between two independent groups, a two-
sided two-sample t-test or Mann–Whitney test
was used for normal and skewed data, respec-
tively, with point estimates of the effect size and
95% CI. Statistical analyses were performed
using R version 3.6.0 with R package ggplot2
[11].
Drugs authorised through the EMA
The number of cancer drugs authorised by the
EMA increased substantially over the study pe-
riod (Fig. 1a, Fig. S1A in the Supplemental in-
formation online). In total, the EMA authorised
97 cancer drugs across 177 cancer indications
from 2000 to 2016. The rate of authorisations
doubled over that time period, with a median of
six per year (range 0–14) from 2000 to 2008, and
13.5 per year (range 8–28) from 2009 to 2016. In
2000, there were eight drugs licensed; in 2016,
there were 28 (Fig. 1a). The increase in EMA
authorisations over time was considerably
greater for high and moderate innovation drugs
than it was for low innovation drugs (Fig. S1b in
the Supplemental information online).
Of the 97 cancer drugs authorised by the EMA,
50 (51%) were classed as highly innovative,
although only 30 (31%) were within the sub-
group showing the very highest level of inno-
vation: acting on a new molecular target or via a
new mechanism of action. Examples include the
CDK4/6 inhibitor, palbociclib, and the immune
checkpoint inhibitor, nivolumab. The proportion patent to patient: analysing access to innovative cancer druof drugs with this very highest degree of in-
novation increased only slightly over time: from
eight of the 30 drugs (27%) authorised by the
EMA from 2000 to 2008, to 22 of the 67 drugs
(33%) from 2009 to 2016 (Fig. 1a).
Despite the increase in EMA authorisations
overall, the number of drugs being licensed for
cancer by the EMA varied markedly by tumour
type. There were large numbers of authorisa-
tions for some cancer types, such as haemato-
logical, skin, and breast cancers, but very few for
others, including several cancers of very high
unmet need (Table 1).
Of note, over one-third (37%) of all of EMA
authorisations were for the treatment of hae-
matological cancers, including five for the tyro-
sine kinase inhibitor imatinib, one of the first
generationofgenetically targeted drugs (Table 1).
There was a steep increase in the number of drug
authorisations for skin cancers, rising from one
approval from 2000 to 2008, to 11 from 2009 to
2016. A total of 15 drugs were authorised by the
EMA for breast cancer: six between 2000 and
2008, and nine between 2009 and 2016.
Authorisations for the treatment of lung cancer
increased sharply, with four between 2000 and
2008, rising to 19 between 2009 and 2016.
By contrast, there were no EMA drug
authorisations at all from 2000 to 2016 for some
cancer types, including brain and oesophageal
cancer, both malignancies of very high unmet
need with 10-year survival rates of 13.5% and
12% respectively, as well as uterine and bladder
cancer. Two further cancers of very high unmet
need, liver and pancreatic cancer, had only one
and four EMA authorisations, respectively, over
this time period (Table 1).
Children are seeing far slower progress in
gaining access to new treatments than adults.
Only eight of the cancer drugs (8%) were
authorised by the EMA for use in children. Across
the 177 drug authorisations by the EMA, only
ten (6%) included a paediatric indication
(Fig. 1b). Six drugs had authorisations for
childhood leukaemias, the most common group
of childhood cancers. Only two drugs were
licensed by the EMA for childhood cancers other
than leukaemias, and there were no drugs with
EMA authorisations for lymphomas or brain
tumours, the second and third most common
groups of cancers in children, respectively
(Fig. 1c).
We analysed the drugs by British National
Formulary (BNF) category (Table 2). The largest
category was the protein kinase inhibitors, ac-
counting for 32 of the 97 drugs (33%), followed
by monoclonal antibodies, of which there were
21 (22%). There were 11 drugs within a broadgs, Drug Discov Today (2020), https://doi.org/10.1016/j.
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FIGURE 1
Analysis of cancer drugs authorised by the European Medicines Agency (EMA) between 2000 and 2016. (a) Number of EMA drug authorisations for cancer
indications from 2000 to 2016, categorised by degree of innovation. (b) EMA authorisations for drugs with paediatric cancer indications from 2000 to 2016 (10),
shown as a fraction of the total (177). (c) EMA paediatric cancer drug authorisations between 2000 and 2016 by cancer type.
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EBNF category of ‘antineoplastics’, while ten were
antimetabolites. We also grouped together five
drugs within a non-BNF category of immuno-
oncology products: monoclonal antibodies
acting as T cell checkpoint inhibitors (ipilimu-
mab, nivolumab, and pembrolizumab), the viral
immunotherapy talimogene laherparepvec, or
T-VEC, and an HPV vaccine.
Length of time from patent to patient
We found that the time it takes to evaluate drugs
in clinical trials and make them available for
patients on the NHS has increased. The meanPlease cite this article in press as: Sharpe, E. et al. From
drudis.2020.01.004time from patent priority date through to a final
appraisal determination by NICE did not short-
en, but instead increased by 1.2 years (95% CI,
–0.71 to 3.16), from 12.8 years for drugs first
authorised by the EMA between 2000 and 2008,
up to 14.0 years for drugs licensed between
2009 and 2016 (Table 3).
We examined each stage in the drug devel-
opment timeline to understand better why it was
taking longer to get drugs from the patent stage
through to NICE approval and availability to
patients on the NHS. The time taken to progress
drugs from patent priority date through to reg- patent to patient: analysing access to innovative cancer druistration of the Phase I trial increased from a
median of 2 years for drugs first authorised by the
EMA from 2000 to 2008 to 3 years for those
licensed from 2009 to 2016, a difference of 1 year
(95% CI, 0 to 2). The average time from the
registration of the initial Phase I trial through to
EMA authorisation also increased significantly by
1.3 years (95% CI, 0.18 to2.5), rising from a meanof
7.7 years for drugs first licensed by the EMA from
2000 to 2008, to 9.0 years for those authorised
from 2009 to 2016 (Table 3).
Figures S2a–c in the Supplemental informa-
tion online display violin plots with embeddedgs, Drug Discov Today (2020), https://doi.org/10.1016/j.
www.drugdiscoverytoday.com 3
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TABLE 1
Number of EMA cancer drug authorisations from 2000 to 2016, categorised by cancer type
Cancer type Authorisations
(2000–2008)
Authorisations
(2009–2016)
Authorisations total
(2000–2016)
% Authorisations
(2000–2016)
Haematological 26 38 64 37%
Lung 4 19 23 13%
Breast 6 9 15 9%
Skin 1 11 12 7%
Bowel 6 5 11 6%
Kidney 4 6 10 6%
Stomach 3 5 8 5%
Prostate 0 6 6 3%
Sarcoma 1 4 5 3%
Thyroid 0 4 4 2%
Pancreatic 2 2 4 2%
Ovarian 0 3 3 2%
Head and neck 3 0 3 2%
Neuroendocrine 1 1 2 1%
Cervical 0 1 1 0.5%
Neuroblastoma (children) 0 1 1 0.5%
Liver 1 0 1 0.5%
Mesothelioma 1 0 1 0.5%
Urinary tract 0 1 1 0.5%
Brain 0 0 0 0%
Womb 0 0 0 0%
Bladder 0 0 0 0%
Oesophageal 0 0 0 0%
Testicular 0 0 0 0%
TABLE 2
Number of EMA cancer drug authorisations from 2000 to 2016, categorised by drug classes listed in the British National Formulary
Class of drug No. of drugs Example
Protein kinase inhibitors 32 Vermurafenib
Monoclonal antibodies 21 Ofatumumab
Antineoplastics 11 Panobinostat
Antimetabolites 10 Clofarabine
lmmuno-oncologya 5 Pembrolizumab
Proteasome inhibitors 3 Bortezomib
Thalidomide and related analogues 3 Lenolidomide
Antiandrogens 2 Abiraterone
Taxanes 2 Cabazitaxel
Alkylating drugs 1 Chlormethine
Anthracyclines and related drugs 1 Pixantrone
Anti-gonadotrophin-releasing hormones 1 Degerelix
Anti-oestrogens 1 Fulvestrant
lmmunostimulants 1 Mifamurtide
Interferons 1 Interferon alpha-2b
Photosensitisers 1 Temoporfin
Plant alkaloids 1 Trabectedin
Retinoid and related drugs 1 Bexarotene
Topoisomerase inhibitors 1 lrinotecan
Vinca alkaloids 1 Vinflunine
Viral vaccine 1 HPV vaccine
aNot a BNF category: includes ipilimumab, nivolumab, and pembrolizumab, which are monoclonal antibodies that act as immune checkpoint inhibitors; T-VEC, which is classed as an
antineoplastic; and the HPV vaccine, which is a viral vaccine.
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taken for patent priority date to registration of
the initial Phase I clinical trial, Phase I registration
to EMA authorisation, and patent priority date to
NICE final appraisal determination, respectively.
We found that the more highly innovative
drugs did not progress faster through devel-Please cite this article in press as: Sharpe, E. et al. From
drudis.2020.01.004
4 www.drugdiscoverytoday.comopment (Table 4, Fig. S3 in the Supplemental
information online). In fact, we observed that
the higher the level of innovation assigned to a
drug, the longer on average it took to move from
patent priority date to NICE final appraisal de-
termination. Highly innovative drugs took a
mean of 14.3 years to progress from the patent patent to patient: analysing access to innovative cancer drupriority date to availability on the NHS, com-
pared with 11.1 years for low innovation drugs,
which was 3.2 years longer (95% CI, 0.20 to 6.17).
Moderate innovation drugs took a mean of 13.5
years, which was 2.4 years longer (95% CI, –0.72
to 5.49) than low innovation drugs. Highly in-
novative drugs also took 2.1 years longergs, Drug Discov Today (2020), https://doi.org/10.1016/j.
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TABLE 3
Analysis of how long it takes for drugs to be made available for patients across two time periods: 2000–2008 and 2009–2016a
Measurement phase EMA drug authorisations
from 2000 to 2008
EMA drug authorisations
from 2009 to 2016
Average different of
(2009 to 2016) –
(2000 to 2008) (95% CI)
Mean (sd) or Medianb
[LQ, UQ] time (in years)
Mean (sd) or Medianb
[LQ, UQ] time (in years)
Patent to Phase I trial registration 2 [0,4]b 3 [2,5]b 1 (0 to 2)
Phase I trial registration to EMA authorisation 7.72 (3.11) 9.04 (3.81) 1.32 (0.18 to 2.45)
Patent to NICE final appraisal determination 12.8 (4.54) 14.0 (4.61) 1.23 (–0.71 to 3.16)
aThe table shows mean (sd) or median [LQ, UQ]b time in years, average difference in years between the time periods 2000 to 2008, and 2009 to 2016, and 95% CI. Data were analysed by t
test or Mann–Whitney testb depending on data distribution.
Abbreviations: sd, standard deviation; LQ, 25th percentile; UQ, 75th percentile.
TABLE 4
Analysis of how long it takes for drugs to be made available for patients, by level of drug innovationb
Measurement phase Low innovation Moderate innovation High innovation
Mean (sd) or Median
[LQ, UQ]b time (in years)
Mean (sd) or Median
[LQ, UQ]b time (in years)
Mean (sd) or Median
[LQ, UQ]b time (in years)
Patent to Phase I trial registration 1 [0, 4.5]b 3 [1.75, 5]b 3 [1,4]b
Phase I trial registration to EMA authorisation 6.77 (2.62) 8.68 (3.12) 8.85 (4.02)
Patent to NICE Final Appraisal Determination 11.09 (4.64) 13.47 (4.42) 14.28 (4.61)
aAbbreviations: LQ, 25th percentile; sd, standard deviation; UQ, 75th percentile.
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drugs to progress from initial Phase I trial reg-
istration through to EMA authorisation (8.9
versus 6.8 years). Moderate innovation drugs
took 1.9 years longer (95% CI, –0.29 to 4.11) than
low innovation drugs (8.7 versus 6.8 years).
Figure S4 in the Supplemental information
online shows violin plots that display the
number of years from patent priority date to
NICE final appraisal determination by innovation
category over the two time periods. We observe
an interesting feature, whereby the median time
taken for the moderate innovation category
increased substantially for Phase I to EMA au-
thorisation (4 years, 95% CI, 2 to 6) and patent
priority date to NICE approval (4 years, 95% CI, 0
to 8). For highly innovative drugs, there was a
slight increase from patent priority date to Phase
I, whereas the time taken for Phase I to EMA
authorisation and patent priority date to NICE
approval were fairly similar across the two time
periods.
We found that NICE has successfully reduced
the lag time between EMA authorisation and the
start of its technology appraisals, from a mean of
21 months for drugs first licensed between 2000
and 2008, down to 6.5 months for drugs licensed
between 2009 and 2016. However, NICE was no
faster at carrying out its appraisals, which took
16.7 months from 2000 to 2008, and 16.0
months from 2009 to 2016.
Taken together, our findings suggest that
cancer drugs have been reaching patients morePlease cite this article in press as: Sharpe, E. et al. From
drudis.2020.01.004slowly because of an increase in the time it takes
for them to move through clinical trials and
licensing, rather than because of delays in
gaining approval from NICE. In addition, the
more highly innovative drugs are progressing
less rapidly than low innovation drugs.
Impact of degree of innovation on NICE
approval
NICE has a key role in ensuring that public
resources are spent on treatments that are good
value for money for the NHS, because drugs
might be licensed by the EMA with only modest
contributions to patient benefit. We wanted to
examine whether NICE was prioritising the most
innovative drugs with the greatest potential for
patient benefit for appraisal and approval.
Of concern, in view of the need for drugs that
work in new ways, our findings suggest that the
system for NICE appraisal has not given priority
to approving the most innovative cancer med-
icines. Among the 97 cancer drugs first licensed
between 2000 and 2016, we found that NICE
recommended for use on the NHS around two-
thirds (66%) of all those that it appraised. This
proportion has remained consistent over the
analysis period, at 67% for drugs licensed be-
tween 2000 and 2008, and 66% for those be-
tween 2009 and 2016. However, drugs
authorised between 2000 and 2016 and classi-
fied as highly innovative were less likely to have
been approved by NICE than lower innovation
medicines (Fig. 2a). Thus, only 38% of highly patent to patient: analysing access to innovative cancer druinnovative cancer drugs had received a positive
recommendation from NICE at the time of our
analysis, compared with 53% of drugs classed as
moderately innovative and 40% of low innova-
tion drugs.
Once NICE evaluates a drug, the chances that
it will say yes are essentially the same regardless
of whether it is a highly innovative treatment.
NICE approved 69% of highly innovative drugs,
compared with 63% of moderately innovative
drugs and 67% of low innovation drugs. How-
ever, NICE was less likely to have appraised
highly innovative drugs than lower innovation
medicines. Only 68% of authorisations for highly
innovative drugs had been appraised by NICE,
compared with 73% of moderately innovative
drugs and 87% of low innovation drugs (Fig. 2B).
Our evidence indicates that highly innovative
drugs were not being prioritised by NICE for
appraisal during the study period.
NICE pledged in 2016 to evaluate all new
cancer drugs in future, giving it the opportunity
to address the discrepancy in appraisal rates for
drugs in different innovation categories. Since
then, the number of cancer drugs that NICE has
appraised has increased; thus, it published 35
technology appraisals in 2016–2017, 45 in 2017–
2018, and 42 in 2018–2019, compared with an
average of 12.8 in the five years previously [12].
Since NICE took over the Cancer Drugs Fund in
April 2016, the proportion of cancer drug
appraisals that have been positive has also in-
creased, to 76% from 59% previously.gs, Drug Discov Today (2020), https://doi.org/10.1016/j.
www.drugdiscoverytoday.com 5
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(a)
(b)
FIGURE 2
Analysis of National Institute of Health and Care Excellence (NICE) approvals of cancer drugs. (a) Percentage of 177 drug authorisations from 2000 to 2016 that
had received a positive recommendation from NICE, categorised by their degree of innovation. (b) Percentage of 177 drug authorisations from 2000 to 2016 that
had started a NICE appraisal at the time of our analysis, categorised by their degree of innovation.
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The factors influencing access to innovative
drugs are wide-ranging and complex and not all
are addressed in the present report. The number
of drugs available for a given cancer indication
depends on not only regulatory approvals, but
also how many drugs are discovered preclini-
cally, start early-phase trials in specific cancer
indications, and then show therapeutic activity.
Here, we focused deliberately and specifically on
drugs that received EMA authorisation (between
2000 and 2016) and analysed their progress
from patent priority date through EMA licensing
and on to NICE approval, which is required for
patient access on the NHS in England and Wales.
In addition, we acknowledge that what is
required is not simply access to drugs, but rather
availability of treatments that make a real dif-Please cite this article in press as: Sharpe, E. et al. From
drudis.2020.01.004
6 www.drugdiscoverytoday.comference to the lives of patients with cancer. Thus,
it is to be expected that NICE (and other health
technology assessment organisations) might
reject some drugs that are approved by the EMA
(or other equivalent regulators) but make only
modest contributions to patient benefit, espe-
cially given the need to prioritise which treat-
ments should be funded by a public healthcare
system with limited resources [13].
Our analysis highlights the progress that is
being made in developing innovative new
cancer medicines. It also draws attention to the
key policy challenges that will need to be
overcome to ensure that patients can benefit
from these advances as quickly as possible.
We found that, as scientific understanding of
cancer has expanded, there has been an in-
crease in the number of new cancer treatments patent to patient: analysing access to innovative cancer drudeveloped and licensed. Targeted drugs, such as
the CDK4/6 inhibitor palbociclib in oestrogen
receptor-positive, HER2-negative metastatic
breast cancers and the PARP inhibitor olaparib
for BRCA-mutant ovarian cancers, together with
immunotherapies, such as the immune check-
point inhibitor nivolumab for melanoma and
several other cancers, are highly innovative and
are giving patients with advanced cancer new
treatment options that are not only extending
survival, but also greatly improving quality of
life.
However, survival remains poor for many
cancer types, and our analysis finds that cancers
of very high unmet need are missing out on the
rapid advances seen in other tumour types. We
need to discover and develop new drugs for
these diseases and to ensure that patients withgs, Drug Discov Today (2020), https://doi.org/10.1016/j.
Drug Discovery Today Volume 00, Number 00  January 2020 PERSPECTIVE
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the same kind of concerted research efforts that
have delivered great progress in other cancer
types, such as breast, skin, and blood cancers.
In paediatric cancers, few targeted drugs are
coming through to the clinic [14,15] and there is
an urgent need to ensure that children with
cancer are able to benefit from advances in
research in the same way that patients with
many adult cancers already are. We need
stronger incentives for pharmaceutical compa-
nies to develop new treatments specifically for
children, and regulations need to be tightened
up to require that adult cancer drugs are eval-
uated in paediatric clinical trials wherever their
mechanism of action is relevant for children [16],
as will be strongly encouraged from 2020 when
new legislation comes into force in the USA [17].
It is important to ensure that innovative
cancer medicines reach patients more quickly.
We found that the average time between the
patent covering the drug being filed and it
becoming available on the NHS had increased
over the analysis period, with it taking longer in
particular to progress from registration of Phase
I trials to authorisation by the EMA. It is possible
that drug development might have been slowed
down by the EU Clinical Trials Directive, which
has been widely regarded as excessively oner-
ous [18,19]. The Directive is due to be replaced
by the EU Clinical Trials Regulation once pre-
paratory work is completed, and it will be im-
portant to closely monitor the effect that this
has on the time it takes to set up and progress
cancer trials.
A range of initiatives have been introduced
over the past five years to try to ensure that
drugs are licensed more quickly, including the
UK’s Early Access to Medicines Scheme [20] and
recent Accelerated Access pathway for innova-
tive treatments [21], and also the European
Union (EU)’s Priority Medicines scheme, PRIME
[22], which provides early dialogue between
companies and the EMA. In addition, the EMA is
able to give conditional market authorisation as
one way of speeding up access to new medi-
cines, with 17 cancer drugs authorised through
this route during a 10-year period between July
2006 and June 2016 [23]. Further research is
required to understand the impact of these
various schemes.
If we are to overcome the major clinical
challenge of the ability of cancer to adapt,
evolve, and become drug resistant, we need
drugs with new mechanisms of action that can
deliver step changes in cancer outcomes, and
can be combined in novel, rationally selected
combinations [3,4]. We believe that more needsPlease cite this article in press as: Sharpe, E. et al. From
drudis.2020.01.004to be done to encourage the pharmaceutical
industry to pursue radical innovation in drug
discovery and development. Pharmaceutical
companies can often be risk averse in taking on
new targets. Many pursue the same small
number of clinically validated targets, some of
which can be subject to more than 20 com-
mercial programmes, leading to duplication and
opportunity cost [24]. Although there is a wel-
come increase in willingness to introduce more
innovation in clinical trial design, with encour-
agement from the EMA and the US Food and
Drug Administration (FDA), there is still some
reluctance to embrace the use of innovative and
streamlined study methodologies, such as
stratified, basket, and adaptive trials [25].
Governments can play a part in stimulating
interactions between universities and industry,
and academic researchers can take a stronger
role in championing more innovative
approaches to drug discovery and development
[7]. Our policies, regulatory systems, and eco-
nomic frameworks must also do more to en-
courage the pharmaceutical industry to
embrace the kind of creative risk taking that is
needed for real innovation. We welcome the fact
that substantial numbers of innovative cancer
drugs with novel mechanisms of action are
being approved and made available for patients,
but it is a concern to see so many companies
working on the same targets [22], while other
promising treatment opportunities based on
highly novel targets are being neglected [26].
Companies and their academic partners should
have greater confidence that innovation in drug
discovery and development will be supported
and rewarded, through more flexible
approaches to the evaluation of trial data, and
by ensuring that the most innovative treatments
are made available for patients as quickly as
possible.
We believe that the EMA could learn from best
practice elsewhere in the world in taking a faster,
more flexible approach to assessing evidence
during drug authorisation. Studies have shown
that the EMA is slower than the FDA at evalu-
ating new drugs, and tends to receive submis-
sions for licensing later [27,28]. We recognise
that the EMA has made some progress in
evolving its approaches to evaluating evidence
[20], but we believe that further changes are
needed to speed up access to markets for the
most innovative treatments. For instance, the
EMA could assess more drugs based on Phase II
trial data, or using endpoints such as progres-
sion-free survival or quality of life improvement
rather than overall survival, with later evaluation
of benefit through assessment of additional real- patent to patient: analysing access to innovative cancer drulife data and follow-up action. Recent data from
2018 show that the FDA approved certain on-
cology drugs based on novel endpoints, namely
metastasis-free survival and minimal residual
disease response rate [29].
We encourage NICE to fast track appraisals of
the most mechanistically innovative cancer
drugs and to take into account their degree of
innovation in deciding whether they should be
approved for patients on the NHS. Worryingly,
our analysis found that highly innovative drugs
were less likely to receive a positive appraisal
from NICE than low innovation medicines. We
believe that NICE’s definition of innovation,
based primarily on effectiveness in areas of
unmet need, is too restrictive and does not do
enough to recognise mechanistic innovation.
We would like to see NICE’s evaluation processes
take greater account of whether a cancer drug is
novel in its drug target or mechanism of action,
unique in a rare disease, or innovative in the way
it is used or delivered. The coming review of
NICE appraisal processes is an opportunity to
improve the way that innovative drugs are
assessed.
It is particularly important to prioritise and
accelerate drugs acting on novel targets and
with novel mechanisms of action, because it is
combinations of such mechanistically innovative
agents that are most likely to have an impact on
overcoming cancer evolution and drug resis-
tance, the major clinical problem we currently
face in cancer treatment.
The low number of drugs coming through for
several tumours with poor clinical outcomes and
for children is of concern. This is likely to be
multifactorial, potentially involving different,
more challenging, or unexplored biology, lower
levels of funding for preclinical academic re-
search on these cancers, and less interest from
pharmaceutical companies, related, for example,
to a lack of previously successful precedents in a
given cancer, market size, prior failures, and,
hence, the calculation or perception of high risk.
We believe that the progress needed to de-
liver big improvements in cancer survival is
eminently achievable, but it will rely on creative
risk taking in drug discovery and development.
We need to find ways of encouraging radical
innovation, and ensuring that the advances
produced reach patients as quickly as possible,
so that more patients with cancer can live lon-
ger, healthier lives.
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